Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

Croatia (1)

Denmark (1)

Hungary (1)

Italy (1)

Montenegro (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovenia (1)

Switzerland (1)

United Arab Emirates (1)

18.11.2014
STADA and mAbxience enter into negotiations over Adalimumab biosimilar
STADA and mAbxience enter into negotiations over Adalimumab biosimilar

STADA and mAbxience enter into negotiations over Adalimumab biosimilar

Read more

13.11.2014
STADA: Good result despite challenging framework conditions – Group sales rise by 4 percent – significant increase of adjusted EBITDA by 12 percent and adjusted net income by 36 percent – outlook for 2014 confirmed
16.10.2014
New STADA initiative investigates daily approach to health
New STADA initiative investigates daily approach to health

New STADA initiative investigates daily approach to health

Read more

13.10.2014
STADA in-licenses teriparatide and further expands biosimilar portfolio
STADA in-licenses teriparatide and further expands biosimilar portfolio

STADA in-licenses teriparatide and further expands biosimilar portfolio

Read more

10.10.2014
STADA plans to hand German logistics business over to a globally active and well-known logistics company
STADA plans to hand German logistics business over to a globally active and well-known logistics company

STADA plans to hand German logistics business over to a globally active and well-known logistics company

Read more

16.09.2014
STADA expands branded product strategy
STADA expands branded product strategy

STADA expands branded product strategy

Read more

07.08.2014
STADA: Solid result in difficult market environment – Group sales increase by 4 percent – adjusted key earnings figures substantially higher than previous year – reported net income approximately at prior-year level
07.08.2014
Interview with Chief Financial Officer Helmut Kraft on the occasion of the half-year results
Interview with Chief Financial Officer Helmut Kraft on the occasion of the half-year results

Interview with Chief Financial Officer Helmut Kraft on the occasion of the half-year results

Read more

30.06.2014
STADA strengthens its branded product portfolio by purchasing the Flexitol® rights for UK and Ireland – a dermatological range in the area of hand and foot care
STADA strengthens its branded product portfolio by purchasing the Flexitol® rights for UK and Ireland – a dermatological range in the area of hand and foot care

STADA strengthens its branded product portfolio by purchasing the Flexitol® rights for UK and Ireland – a dermatological range in the area o…

Read more

04.06.2014
STADA Executive Board shows satisfaction with financial year 2013 at Annual General Meeting and adheres to outlook for 2014
STADA Executive Board shows satisfaction with financial year 2013 at Annual General Meeting and adheres to outlook for 2014

STADA Executive Board shows satisfaction with financial year 2013 at Annual General Meeting and adheres to outlook for 2014

Read more

04.06.2014
Three questions for Chairman of the Executive Board Hartmut Retzlaff
Three questions for Chairman of the Executive Board Hartmut Retzlaff

Three questions for Chairman of the Executive Board Hartmut Retzlaff

Read more

20.05.2014
STADA subsidiary supports victims of Balkan flood
STADA subsidiary supports victims of Balkan flood

STADA subsidiary supports victims of Balkan flood

Read more